

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Advances in Cancer Immunotherapy (C4)

March 22-26, 2020 • Fairmont Chateau Whistler • Whistler, BC, Canada

Scientific Organizers: Antoni Ribas, W. Nicholas Haining and Priti Hegde

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Compass Therapeutics, Gilead Sciences, Inc., Genentech, Inc., Incyte Corporation, MorphoSys AG and Surface Oncology

Discounted Abstract & Scholarship Deadline: November 19, 2019 / Abstract Deadline: December 17, 2019 / Discounted Registration Deadline: January 22, 2020

SUNDAY, MARCH 22

Arrival and Registration

MONDAY, MARCH 23

Welcome and Keynote Address

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
Tumor Recognition by the Human T Cell Pool

New Approaches to Adoptive T Cell Transfer Therapy

Malcolm K. Brenner, Baylor College of Medicine, USA
ACT - Natural Selection Versus Intelligent Design

Crystal L. Mackall, Stanford University, USA
CAR T Cell Engineering

Yvonne Y. Chen, University of California, Los Angeles, USA
Engineering Smarter and Stronger T Cells for Cancer Immunotherapy

Short Talks Chosen from Abstracts

Response and Resistance to Cancer Immunotherapy

Jane Oliaro, Peter MacCallum Cancer Centre, Australia
A Role for TNF in Anti-Tumour Immunity and Resistance to Immunotherapy

Charles Swanton, Francis Crick Institute, UK
Immunogenomic Mechanisms of Resistance to Immunotherapy

W. Nicholas Haining, Merck Research Laboratories, USA
Genetic Screens for Immunotherapy Targets

Short Talks Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 24

Igniting an Immune Response to Cancer

Ira Mellman, Genentech, Inc., USA
Mechanistic Basis of Cancer Immunotherapy

Padmanee Sharma, University of Texas MD Anderson Cancer Center, USA
From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy

Zhijian "James" Chen, University of Texas Southwestern Medical Center, USA
Igniting Anti-Tumor Immunity with cGAS

Sohail F. Tavazoie, Rockefeller University, USA
Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy

Short Talks Chosen from Abstracts

Epigenetic Control of Cancer Immunotherapy

Howard Y. Chang, Stanford University, USA
Epigenetic Regulation of Cancer and Immune Cells

E. John Wherry, University of Pennsylvania, USA
Epigenetic Features of Exhausted Antitumor T Cells

Confluence of Engineering and Cancer Immunotherapy

Vanessa Peterson, Merck, USA

Uncovering Novel T Cell Biology with Multi-Omics Single Cell Sequencing and Whole Genome CRISPR Screening

Evan Scott, Northwestern University, USA

Engineered Nanobiomaterials for Cancer Immunotherapy

James R. Heath, Institute for Systems Biology, USA

Microfluidics and Nanotechnology Approaches to Analyzing Antitumor Responses

Poster Session 2

WEDNESDAY, MARCH 25

Orchestrating Antitumor Immune Responses

Robert D. Schreiber, Washington University School of Medicine, USA
Immunoediting in Cancer

Priti Hegde, Foundation Medicine, USA

Talk Title to be Announced

Thomas Gajewski, University of Chicago, USA

Microbiome and Immune Responses to Cancer

Siwen Hu-Lieskovan, Huntsman Cancer Institute, USA

Talk Title to Be Announced

Short Talks Chosen from Abstracts

Understanding Immune Responses at the Genomic Level

Elaine R. Mardis, Nationwide Children's Hospital, USA

Exploring the Pediatric Cancer Tumor Microenvironment: Clinical Impact

Eliezer Van Allen, Dana-Farber Cancer Institute, USA

Genetic Escape from Cancer Immunotherapy

Short Talks Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 26

Keynote Address

James P. Allison, University of Texas MD Anderson Cancer Center, USA

Distinct Mechanisms of Action of Immune Checkpoint Inhibitors

Treating Cancer with the Immune System

Georgina V. Long, Melanoma Institute Australia, The University of Sydney, Australia

Clinical Trials with Activators of Pattern Recognition Receptors or Oncolytic Viruses

Antoni Ribas, University of California, Los Angeles, USA

Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy

Short Talks Chosen from Abstracts

Combination Immunotherapies

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Advances in Cancer Immunotherapy (C4)

March 22-26, 2020 • Fairmont Chateau Whistler • Whistler, BC, Canada

Scientific Organizers: Antoni Ribas, W. Nicholas Haining and Priti Hegde

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Compass Therapeutics, Gilead Sciences, Inc., Genentech, Inc., Incyte Corporation, MorphoSys AG and Surface Oncology

Discounted Abstract & Scholarship Deadline: November 19, 2019 / Abstract Deadline: December 17, 2019 / Discounted Registration Deadline: January 22, 2020

Ansuman Satpathy, Stanford University School of Medicine, USA

Single-Cell Genomics in Cancer Immunotherapy

Arlene H. Sharpe, Harvard Medical School, USA

Effects of PD-1 Blockade Therapy

Juan C. Jaen, Arcus Biosciences, Inc., USA

Adenosine Pathway Inhibitors

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, MARCH 27

Departure